Shoulder Innovations, Inc. (NYSE:SI – Get Free Report) major shareholder Healthcare Holding B.V. Gilde sold 2,095 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $22.60, for a total value of $47,347.00. Following the completion of the sale, the insider directly owned 2,212,207 shares of the company’s stock, valued at $49,995,878.20. The trade was a 0.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Healthcare Holding B.V. Gilde also recently made the following trade(s):
- On Wednesday, August 5th, Healthcare Holding B.V. Gilde sold 7,338 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.64, for a total transaction of $166,132.32.
- On Tuesday, August 4th, Healthcare Holding B.V. Gilde sold 99,812 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.77, for a total transaction of $2,272,719.24.
- On Monday, August 3rd, Healthcare Holding B.V. Gilde sold 10,751 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.71, for a total transaction of $244,155.21.
- On Friday, July 31st, Healthcare Holding B.V. Gilde sold 20,034 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.73, for a total transaction of $455,372.82.
- On Thursday, July 30th, Healthcare Holding B.V. Gilde sold 28,245 shares of Shoulder Innovations stock. The stock was sold at an average price of $23.36, for a total transaction of $659,803.20.
Shoulder Innovations Stock Performance
Shares of SI opened at $20.54 on Monday. The company has a debt-to-equity ratio of 0.12, a current ratio of 10.71 and a quick ratio of 8.92. Shoulder Innovations, Inc. has a one year low of $10.92 and a one year high of $24.59. The company has a 50-day simple moving average of $19.91 and a two-hundred day simple moving average of $16.09. The firm has a market capitalization of $427.71 million and a PE ratio of -10.70.
Analysts Set New Price Targets
SI has been the subject of several recent research reports. Piper Sandler reissued an “overweight” rating and set a $25.00 price objective (up from $19.00) on shares of Shoulder Innovations in a research report on Friday. Weiss Ratings raised shares of Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. BTIG Research increased their price target on shares of Shoulder Innovations from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday. Finally, UBS Group began coverage on shares of Shoulder Innovations in a research report on Tuesday, July 28th. They set a “buy” rating and a $27.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.33.
View Our Latest Stock Analysis on Shoulder Innovations
Institutional Investors Weigh In On Shoulder Innovations
Institutional investors have recently modified their holdings of the stock. Roubaix Capital LLC grew its position in Shoulder Innovations by 61.9% during the 1st quarter. Roubaix Capital LLC now owns 257,121 shares of the company’s stock valued at $3,736,000 after purchasing an additional 98,305 shares during the last quarter. Sectoral Asset Management Inc. raised its holdings in Shoulder Innovations by 14.4% in the fourth quarter. Sectoral Asset Management Inc. now owns 492,435 shares of the company’s stock worth $7,042,000 after buying an additional 62,153 shares during the last quarter. KCM Capital Inc bought a new position in shares of Shoulder Innovations in the first quarter worth approximately $509,000. Royal Bank of Canada grew its holdings in shares of Shoulder Innovations by 7,046.3% during the first quarter. Royal Bank of Canada now owns 53,883 shares of the company’s stock valued at $783,000 after buying an additional 53,129 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Shoulder Innovations by 66.3% during the fourth quarter. Wells Fargo & Company MN now owns 5,250 shares of the company’s stock valued at $75,000 after acquiring an additional 2,094 shares in the last quarter.
Shoulder Innovations News Summary
Here are the key news stories impacting Shoulder Innovations this week:
- Positive Sentiment: Analysts raised their targets: Piper Sandler reaffirmed its “overweight” rating and lifted its price target from $19 to $25, while BTIG Research raised its target from $24 to $26 and initiated a “buy” rating. These targets imply meaningful upside and may support investor sentiment. Benzinga analyst rating updates
- Positive Sentiment: Revenue growth remained strong: Second-quarter revenue increased approximately 56% year over year to $17.2 million, slightly exceeding estimates. Gross profit rose about 60%, indicating continued demand and improving product economics. Shoulder Innovations Q2 2026 earnings summary
- Positive Sentiment: Full-year guidance was raised: SI forecast fiscal-year revenue of $67 million to $69 million, broadly in line with the roughly $67.1 million consensus estimate. Management also highlighted 60% first-half revenue growth. Shoulder Innovations raises full-year outlook
- Neutral Sentiment: Liquidity appears adequate but is declining: The company ended the quarter with $24.5 million in cash and used $7.4 million in operating activities and $2.2 million in capital expenditures. Investors will likely monitor whether revenue growth can lead to improved cash generation.
- Negative Sentiment: Profitability remains a concern: SI reported an operating loss of about $10 million, a net loss of approximately $10.2 million, and diluted EPS near negative $0.49, missing some estimates. The company remains deeply unprofitable, increasing valuation sensitivity. Shoulder Innovations quarterly results
- Negative Sentiment: Major-holder selling may weigh on sentiment: Gilde Healthcare sold more than 110,000 shares in early August for roughly $2.5 million. Although it retains a substantial stake, the sales can raise concerns about near-term supply and insider conviction. Gilde Healthcare insider sale
Shoulder Innovations Company Profile
Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.
In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.
Featured Articles
- Five stocks we like better than Shoulder Innovations
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Shoulder Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shoulder Innovations and related companies with MarketBeat.com's FREE daily email newsletter.
